Natasha Persaud

Up to 40% of patients hospitalized with urinary tract infection unnecessarily receive extended-spectrum antibiotics.

Although viral infection is a potential cause of painful interstitial cystitis, few previous studies have examined antiviral treatment.

Patients with accelerated HBV vaccination who experience seroconversion might be eligible to receive a kidney transplant from a hepatitis B-positive donor.

The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout.

Ondansetron, a commonly prescribed antiemetic, is known to prolong the QT interval.

New findings raise questions about the reliability of estimated glomerular filtration rate as a basis for clinical decision-making.

Decline in eGFR early after tolvaptan administration can be easily measured in routine clinical practice.

Real-world data support the anemia reduction found in post hoc analyses of the CREDENCE and DAPA-CKD trials.

This phase 3 trial is the first to assess the efficacy and safety of a novel EPO-mimetic since the withdrawal of peginesatide from the market.

Together with previous research, this analysis suggests a new therapeutic approach for treating anemia in the CKD population.